Miguel F Sanmamed,Xinxin Nie,Shruti S Desai,Franz Villaroel-Espindola,Ti Badri,Dejian Zhao,Anthony W Kim,Lan Ji,Tianxiang Zhang,Edward Quinlan,Xiaoxiao Cheng,Xue Han,Matthew D Vesely,Ala F Nassar,Jingwei Sun,Yu Zhang,Tae Kon Kim,Jun Wang,Ignacio Melero,Roy S Herbst,Kurt A Schalper,Lieping Chen,Miguel F. Sanmamed,Shruti S. Desai,Anthony W. Kim,Matthew D. Vesely,Ala F. Nassar,Roy S. Herbst,Kurt A. Schalper

Abstract:Abstract Specific mechanisms by which tumor-infiltrating lymphocytes (TIL) become dysfunctional remain poorly understood. Here, we employed a two-pronged approach using single-cell mass cytometry and tissue imaging technologies to dissect TILs from 25 patients with resectable and 35 patients with advanced non–small cell lung cancer (NSCLC). We identified a burned-out CD8+ TIL subset (Ebo) that specifically accumulated within the tumor microenvironment (TME) but not in adjacent nontumoral tissues. Ebo showed the highest expression of proliferation and activation markers but produced the lowest amount of IFNγ and were the most apoptotic CD8+ TIL subset. Using a humanized patient-derived tumor xenograft model, we demonstrated that Ebo expansion occurred within the TME in a PD-1/B7-H1 pathway-dependent manner. Ebo abundance in baseline tumor tissues was associated with resistance to anti-PD therapy in patients with NSCLC. Our study identifies a dysfunctional TIL subset, with distinct features from previously described exhausted T cells, and implies strategies to overcome immunotherapy resistance. Significance: We identified a highly proliferative, overactivated, and apoptotic dysfunctional CD8+ tumor-infiltrating subpopulation that is functionally distinct from previously described exhausted T cells. This population is expanded in lung cancer tissues in a PD-1/B7-H1-dependent manner, and its abundance is associated with resistance to cancer immunotherapy, thus becoming a potential tissue biomarker. This article is highlighted in the In This Issue feature, p. 1601

Supplementary Fig. S8 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T cell–Secreted Cytokines

Supplementary Fig. S7 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Fig. S5 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Data from Tumor-Derived Small Extracellular Vesicles Inhibit the Efficacy of CAR T Cells against Solid Tumors

Supplementary Fig. S4 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Table S3 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Data from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Table S1 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplemental Figure S2 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy

Supplementary Figure S7 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Supplementary Figure S6 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure 8 from TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis

Pan-cancer mapping of single CD8+ T cell profiles reveals a TCF1:CXCR6 axis regulating CD28 co-stimulation and anti-tumor immunity

A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy

Supplementary Figure S8 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplementary Figure S8 from Breast Cancer Stem Cells Secrete MIF to Mediate Tumor Metabolic Reprogramming That Drives Immune Evasion

Supplementary Figure S10 from Targeting the Dendritic Cell-Secreted Immunoregulatory Cytokine CCL22 Alleviates Radioresistance

Supplemental Figure S5 from Cytokine-like Molecule CCDC134 Contributes to CD8+ T-cell Effector Functions in Cancer Immunotherapy